Startup Dossier
Biomunex Pharmaceuticals
Paris- and Cambridge-based biopharmaceutical company pioneering a new generation of bi- and multi-specific antibodies for cancer immunotherapy. Its proprietary BiXAb® “Plug-and-Play” platform enables the rapid development of bispecific antibodies with strong druglike properties. Biomunex is the first to develop MAIT-engagers—bispecific antibodies designed to identify, mobilize, and activate MAIT cells, a subpopulation of T cells capable of killing cancer cells.
About
Paris- and Cambridge-based biopharmaceutical company pioneering a new generation of bi- and multi-specific antibodies for cancer immunotherapy. Its proprietary BiXAb® “Plug-and-Play” platform enables the rapid development of bispecific antibodies with strong druglike properties. Biomunex is the first to develop MAIT-engagers—bispecific antibodies designed to identify, mobilize, and activate MAIT cells, a subpopulation of T cells capable of killing cancer cells.
Structural DNA
Legal Name
Biomunex Pharmaceuticals
SIREN
800768939
Founders & Team
Funding Lineage
Growth
2 investors
€0
Oct 2025